CERO (CERo Therapeutics Holdings) Long-Term Debt: $0.14 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Long-Term Debt?

CERo Therapeutics Holdings CERO -12.75% Long-Term Debt is $0.14 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

CERo Therapeutics Holdings's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.14 Mil.

CERo Therapeutics Holdings's quarterly Long-Term Debt stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.14 Mil).

CERo Therapeutics Holdings  (OTCPK:CERO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

CERo Therapeutics Holdings Long-Term Debt Related Terms

CERo Therapeutics Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Long-Term Debt Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00 0.00 0.00

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.14
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.14 Mil mean?
CERo Therapeutics Holdings (CERO) has a Long-Term Debt of $0.14 Mil as of Mar. 2026.
Is CERo Therapeutics Holdings' Long-Term Debt too high?
CERo Therapeutics Holdings' current Long-Term Debt is $0.14 Mil.
How does CERo Therapeutics Holdings' Long-Term Debt compare to WINT and LIPO?
CERo Therapeutics Holdings' Long-Term Debt of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. CERo Therapeutics Holdings's current Long-Term Debt is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Long-Term Debt of $0.14 Mil. The current Long-Term Debt is $0.14 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Long-Term Debt is $0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.